The short answer
Safety depends on four variables: the peptide itself, the prescriber, the compounding pharmacy, and the supervision model. Get all four right and the safety profile of most clinically used peptides is well within the norms of compounded medical care. Get any of them wrong and the risk profile rises sharply.
Safety by category
| FDA status | Evidence base | Typical risks | Genesis approach | |
|---|---|---|---|---|
| Tesamorelin | FDA-approved for HIV lipodystrophy | Phase III RCTs | Joint pain, fluid retention, glucose effects | Provider-monitored; dose titration |
| PT-141 (Vyleesi) | FDA-approved for HSDD | Phase III RCTs | Nausea, transient blood pressure rise | Used at lowest effective dose |
| GHK-Cu | 503A compounded | In vitro + small human trials | Generally well-tolerated topically/SubQ | Disclosed as emerging evidence |
| BPC-157 | 503A compounded | Preclinical + small Croatian trials | Self-reported tolerability good; no large safety RCT | Disclosed as emerging; not for cancer history |
| MOTS-C, Epitalon | Research-only | Preclinical only | Unknown long-term | Disclosed as weak evidence; informed consent |
Where the safety risk actually comes from
Most adverse outcomes attributed to 'peptides' in the lay media trace back to one of three sources: research-grade peptides purchased online without prescription or sterility guarantees, dosing errors from self-administration, and undisclosed contraindications such as active cancer or uncontrolled diabetes. Genesis only prescribes peptides through 503A pharmacies, with provider supervision and clinical monitoring tied to the relevant axis.
What an evidence-graded approach looks like
We grade every therapy on a five-tier scale (strong, moderate, emerging, weak, very weak). The grade is shown on every therapy page. A patient choosing BPC-157 sees emerging evidence and the underlying preclinical and small-trial sources; a patient choosing tesamorelin sees strong and the FDA approval and Phase III trials. The grade does not change whether you can access the therapy; it changes whether you make an informed decision.